News in Gastric Cancer

News from around the world, curated by the Gastric Cancer Foundation.
Manufacturer's illustration of how Keytruda stops cancer cells hiding from the immune system.

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

A new study published in The Lancet finds Keytruda, the PD-1 antibody pembrolizumab, may offer a better safety profile but does not improve outcomes compared with paclitaxel.

Read Source
X